The $2.97 price target is fundamentally flawed. T
Post# of 30028
Posted On: 03/12/2016 2:03:31 PM
Re: MikeChavelle #22800
The $2.97 price target is fundamentally flawed. They put that price target on it currently - that is with 98M shares outstanding. Then they go on to back up their price target and talk almost exclusively about the post-closing Avant.
Post-closing, there will be 203M shares outstanding.
So, $291M market cap divided by 203M shares and the post-closing price target is $1.43 a share.
Remember, this is the same outfit that put a $43 price target on AMBS both pre-toxic financing and post-toxic financing. Made no sense.
As much as I love these price targets, you absolutely can put no stock in SeeTruEquity.
Post-closing, there will be 203M shares outstanding.
So, $291M market cap divided by 203M shares and the post-closing price target is $1.43 a share.
Remember, this is the same outfit that put a $43 price target on AMBS both pre-toxic financing and post-toxic financing. Made no sense.
As much as I love these price targets, you absolutely can put no stock in SeeTruEquity.
Quote:
More than i could've asked. That's a great starting point for me. I will continue to do DD as well. (I'll pass a long any nuggets, if i find some) I swear I'm not a lazy investor lol, I've just been busy with work and i was a little bit confused of what all of this means for the 3 entities involved in this merge of sorts.
Thank you for providing clarity RED!
(4)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼